Agilent Technologies, Inc. (A) fair value analysis
S&P 500 · Updated 2026-10-19
A price how computed
Forward Fair Value verdict
Fairly valuedA is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $170.54
- Sector
- Healthcare
- 12-month range
- $110.24–$175.55
- Market cap
- $48.1B
- From 52-week high
- -2.9%
- Shares outstanding
- 282M
- Rank in Healthcare by discount to fair value
- #62 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Agilent Technologies, Inc. is a diversified healthcare and life sciences company that develops, manufactures, and sells analytical instruments, software, and services used in laboratories and clinical settings worldwide. The company operates through multiple business segments serving pharmaceutical, chemical, food, environmental, and academic customers across North America, Europe, Asia-Pacific, and other international markets.
A currently ranks #62 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $48.1B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $7.37B
- Net margin
- 19.5%
- EPS (TTM)
- $6.06
- Gross margin
- 55.5%
- Debt / equity
- 0.54
- Revenue growth (3-yr avg)
- 3.8%
- Shares outstanding
- 282M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 67 · neutral
- 50-day average
- $158.89
- 200-day average
- $134.50
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $1.02 per share (4 payments)
- Yield on last price
- 0.60%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-10-06
- Last payment date
- 2026-10-28
Earnings how computed
- Next earnings report
- 2026-11-23
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-07 ▲ beat (+9.5%)
2026-04 ▲ beat (+5.7%)
2026-01 ▼ miss (-0.7%)
2025-10 ▲ beat (+0.6%)
2025-07 ▬ met (0.0%)
2025-04 ▲ beat (+4.0%)
2025-01 ▲ beat (+3.1%)
2024-10 ▲ beat (+3.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 7 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $181
- Target vs last price
- +6.1%
What our data shows for A
- Our model validated 17 trailing price-to-earnings windows for A, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $110.24–$175.55.
- The 14-day relative strength index sits at a neutral 67.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for A
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent A news
TickrTrends' derived news-sentiment signal for A is currently leaning positive, computed from recent coverage.
- Is A Overvalued? DCF Says Worth $120 (gurufocus.com, 2026-10-14)
TickrTrends take: A recent discounted cash flow analysis valued the company at $120, presenting a reference point for investors evaluating the stock against TickrTrends' current assessment of fair valuation. Since DCF models are sensitive to assumptions about future growth, cash flows, and discount rates, readers should monitor whether management guidance or industry trends shift these underlying inputs. The gap between any DCF estimate and current market pricing can help indicate whether the market is pricing in different expectations for the Healthcare sector company's future performance. - A Maintained by TD Cowen -- Price Target Raised to $196 (gurufocus.com, 2026-10-13)
TickrTrends take: TD Cowen's decision to maintain its rating while raising the price target to $196 suggests analyst confidence in A's underlying fundamentals, even as market conditions evolve. Given that TickrTrends currently rates A as fairly valued, the raised price target indicates that external analyst perspectives may be tracking ahead of broader valuation consensus. For valuation-focused readers monitoring this Healthcare sector company, the gap between the new target and current market pricing warrants attention as a potential indicator of how fundamental expectations are shifting relative to the stock's current assessment. - Agilent Technologies (A) Acquires Proscia to Expand Digital Pathology Capabilities (gurufocus.com, 2026-10-13)
TickrTrends take: Agilent Technologies' acquisition of Proscia represents a strategic move to strengthen its position in the digital pathology market, an area gaining importance as healthcare providers increasingly adopt digital workflows. With Agilent currently assessed as fairly valued by TickrTrends, investors focused on valuation should monitor whether this acquisition generates sufficient margin expansion or market share gains to justify any integration costs or goodwill that appears on future balance sheets. The effectiveness of this digital pathology expansion in driving revenue growth relative to the company's current valuation multiple will be a key metric to track in upcoming earnings reports.
More A news
- Agilent Technologies Inc (A) Shares Fall 3.3% -- GF Value Says Still Overvalued (gurufocus.com, 2026-10-01)
What people are saying
Follow the A conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for Healthcare sector A show a shift this week as the Relative Strength Index moved from overbought territory into neutral zone, suggesting a moderation in recent momentum. The stock maintains a fairly valued status based on current valuation metrics. This transition reflects a cooling of the short-term buying pressure that had characterized the previous week.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for A in the Healthcare sector show a shift in momentum this week, with the RSI zone moving from neutral to overbought territory. The stock maintains a fairly valued assessment based on current valuation metrics. This overbought reading suggests the recent price movement has outpaced typical momentum levels for the stock.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for the Healthcare sector (A) shifted this week, with the sector discount rank declining from 58 to 66, indicating a reduced relative valuation advantage compared to other sectors. The valuation verdict changed from Undervalued to Fairly valued, reflecting the sector's adjusted positioning in the broader market context.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is A stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), A is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is A's TickrTrends verdict?
A's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does A compare to other Healthcare stocks?
A ranks #62 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is A overbought or oversold?
A's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does A pay a dividend?
Yes. A paid $1.02 per share over the last twelve months (4 payments), a 0.60% yield on TickrTrends' last price. The last ex-dividend date was 2026-10-06.
When does A report earnings next?
A's next earnings report is scheduled for 2026-11-23, per the published earnings calendar.
Does A usually beat earnings estimates?
Over its last 8 reported quarters A beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about A?
Of 22 analysts covering A, 15 rate it a buy, 7 a hold and 0 a sell - buy-leaning, with a consensus price target of $181 (+6.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.